- Report
- January 2021
- 900 Pages
United States
From €3180EUR$3,300USD£2,735GBP
- Report
- January 2019
- 35 Pages
Global
From €964EUR$1,000USD£829GBP
Halaven is a brand of chemotherapy drug used to treat metastatic breast cancer and metastatic non-small cell lung cancer (NSCLC). It is a type of epothilone, a class of drugs that work by inhibiting the growth of cancer cells. Halaven is administered intravenously and is used in combination with other chemotherapy drugs. It is approved by the US Food and Drug Administration (FDA) for the treatment of metastatic breast cancer and metastatic NSCLC.
Halaven is a relatively new drug, having been approved by the FDA in 2015. It is marketed by Eisai, a Japanese pharmaceutical company. The drug is available in the United States, Europe, and other countries.
Halaven is one of several drugs used to treat metastatic lung cancer. Other drugs used to treat this condition include Alimta, Taxotere, and Gemzar. These drugs are used in combination with other chemotherapy drugs to treat metastatic lung cancer.
In the market for lung cancer drugs, Halaven is one of several drugs used to treat metastatic lung cancer. Companies that market drugs for this condition include Eisai, Eli Lilly, Merck, Pfizer, and AstraZeneca. Show Less Read more